Oppenheimer raises Kymera Therapeutics price target on drug data
Oppenheimer raised its price target for Kymera Therapeutics (NASDAQ:KYMR) to $140 from $125, citing positive drug trial results and Q3 financials. The stock is near its 52-week high. Kymera reported a Q3 loss of $1.32 per share, slightly missing estimates, but has $1.6B in cash. Brookline Capital also raised its target to $132.
How this was made
The 30-second read
Why it matters
The trial data provides a tangible proof‑of‑concept that could de‑risk the pipeline and justify a higher valuation.
Market read
Analyst upgrade driven by trial data may trigger short‑term buying interest in KYMR.
What to watch
Potential regulatory delays or competition in the atopic dermatitis space.
Background
Kymera Therapeutics reported Q3 results with a small earnings miss but highlighted a healthy‑volunteer study of its KT‑579 degrader.
Ticker impact
Oppenheimer raised its price target to $140 after reporting positive Phase 2 data from the KT-579 study and Q3 earnings.
likely upward pressure as investors price in the favorable trial results and higher target.
The study showed >90% IRF‑5 degradation across doses, and the analyst upgrade adds a concrete catalyst for buying.
Market effects
Positive data may lift peer biotech stocks focused on transcription factor targeting.
US biotech sector could see modest gains.
Limited to biotech investors; no broad market effect.
Counterpoint
If the data does not translate to clinical efficacy, the stock could be overbought after the upgrade.
Key entities
- companyKymera Therapeutics
Biotech firm developing targeted protein degradation therapies.
- analystOppenheimer
Equity research firm that raised the price target.
